Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure – guidance (TA626)

Avatrombopag is recommended as an option for treating severe thrombocytopenia (platelet count of <50,000/microlitre of blood) in adults with chronic liver disease having a planned invasive procedure.

National Institute for Health and Care Excellence